Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Enfuvirtide].

Ladislav Machala1

  • 1Clinic of Infectious Diseases, Faculty Hospital Na Bulovce, Prague 8, Czech Republic, ladimachala@hotmail.com

Klinicka Mikrobiologie a Infekcni Lekarstvi
|July 1, 2004
PubMed
Summary
This summary is machine-generated.

Enfuvirtide, a new fusion inhibitor, blocks HIV entry into cells by targeting glycoprotein 41. This synthetic peptide is administered subcutaneously for salvage therapy in treatment-experienced patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccination coverage against COVID-19 among people living with HIV infection in the Czech Republic.

Central European journal of public health·2026
Same author

Corrigendum to "Demographic, epidemiological and clinical characteristics of Ukrainian war refugees with HIV infection in the Slovak Republic" [Travel Med Infect Dis 62 (2024) 102764].

Travel medicine and infectious disease·2024
Same author

Demographic, epidemiological and clinical characteristics of Ukrainian war refugees with HIV infection in the Slovak Republic.

Travel medicine and infectious disease·2024
Same author

The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease-A report from Central and Eastern Europe.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2020
Same author

Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae co-infections among patients with newly diagnosed syphilis: a single-centre, cross-sectional study.

Central European journal of public health·2020
Same author

Cross-sectional study on vaccination coverage in newly diagnosed HIV-infected persons in the Czech Republic.

Central European journal of public health·2019

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Enfuvirtide represents a novel class of antiretrovirals: fusion inhibitors.
  • It targets the Human Immunodeficiency Virus (HIV) glycoprotein 41 (gp41) HR1 domain.
  • Approved for clinical use, it offers a new therapeutic option.

Purpose of the Study:

  • To introduce enfuvirtide as a fusion inhibitor.
  • To explain its mechanism of action in blocking viral entry.
  • To highlight its role in salvage therapy for multiresistant HIV.

Main Methods:

  • Enfuvirtide is a synthetic peptide composed of 36 amino acids.
  • Its mechanism involves binding to the HR1 domain of HIV gp41.
  • Administration is limited to subcutaneous injection due to instability in the gastrointestinal tract.

Related Experiment Videos

Main Results:

  • Enfuvirtide effectively inhibits the fusion of HIV with host target cells.
  • It acts by preventing the conformational changes necessary for viral entry.
  • Clinical use is established for salvage therapy.

Conclusions:

  • Enfuvirtide is a valuable therapeutic agent for patients with limited treatment options.
  • Its unique mechanism of fusion inhibition provides an alternative to other antiretroviral classes.
  • Effective management of multiresistant HIV is enhanced by its availability.